All HHS Contracts — January 21, 2026

Acumen secured $89M total (44% of stream) in firm-fixed and cost-plus awards for payment methodologies, with 74% outlayed signaling execution strength.

Public Health Vaccines' $55M contract (options to $101M) provides long-term funding through 2028 for Marburg vaccine amid biotech demand.

Largest award ($58M, 28% of stream) to nonprofit Seneca limits investable upside despite behavioral health focus.

Long tenures (2026-2028 ends) with partial outlays (avg 60%) expose to delays or non-exercise of $60M+ options.

Time/cost-plus pricing in 50% of contracts invites cost scrutiny; COVID/CMS focus risks priority shifts.

$60M unexercised options (30% of total value) across contracts, plus extensions to 2027-2028.

Acumen's $89M in data/methodology awards highlights demand for HHS payment analytics amid Provider Relief and bundled payments.

45% to consulting (Acumen) and 27% to biotech R&D underscore sustained federal spend on data analytics and vaccines despite COVID fade.

All awards extend 4-10 years from HHS sub-agencies, with 60% avg outlay providing backlog visibility.

{"entity"=>"Acumen LLC", "reason"=>"45% stream capture via repeat awards in high-outlay ($42M+ each) payment consulting.", "trigger"=>"New HHS task orders or option exercises exceeding $10M"}

{"entity"=>"Public Health Vaccines LLC", "reason"=>"$55M BARDA vaccine contract with $46M options and 2028 horizon amid biothreat focus.", "trigger"=>"Milestone payments or BARDA expansions pushing outlays >50%"}